On August 20, CSPC PHARMA rose 12.49% in regular trading, trading at 9.9 HKD/share, with turnover of HKD 2.43 billion. The surge coincided with the company's board meeting to approve interim results, with multiple positive developments converging to drive the stock higher.

On the news front, subsidiary CSPC Innovation Pharmaceutical had already disclosed H1 results showing revenue of approximately RMB 32.4 billion, up 208.72% year-over-year, and net profit of approximately RMB 12.61 billion, representing a turnaround from loss to profit. BD cooperation monetization and biologics commercialization acceleration were cited as core growth drivers. Additionally, the company recently confirmed receipt of a USD 30 million upfront payment from AstraZeneca for an siRNA drug collaboration, following a separate USD 10 million milestone payment under an oral small-molecule partnership. The company also received NDA acceptance with priority review for Anbenitamab combination therapy for HER2-positive breast cancer, and initiated multiple clinical trials including SYS 6090 for liver and colorectal cancers and SYS6063 CAR-T for lupus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)